KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $251.4 million.

  • Jazz Pharmaceuticals' Profit After Tax rose 1690.59% to $251.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.9 million, marking a year-over-year decrease of 11314.62%. This contributed to the annual value of $560.1 million for FY2024, which is 3502.33% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Profit After Tax stood at $251.4 million for Q3 2025, which was up 1690.59% from -$718.5 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' Profit After Tax's 5-year high stood at $251.4 million during Q3 2025, with a 5-year trough of -$718.5 million in Q2 2025.
  • Moreover, its 5-year median value for Profit After Tax was $52.0 million (2022), whereas its average is -$2.5 million.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Profit After Tax tumbled by 58095.39% in 2022 and then soared by 411493.62% in 2023.
  • Jazz Pharmaceuticals' Profit After Tax (Quarter) stood at -$35.4 million in 2021, then crashed by 580.95% to -$240.7 million in 2022, then surged by 139.11% to $94.2 million in 2023, then skyrocketed by 102.98% to $191.1 million in 2024, then surged by 31.55% to $251.4 million in 2025.
  • Its Profit After Tax was $251.4 million in Q3 2025, compared to -$718.5 million in Q2 2025 and $191.1 million in Q4 2024.